bioMérieux - Business Review for the nine months ended September 30, 2009

Marcy l'Etoile, France - October 20, 2009. 2009 Nine-Month Sales

• up 7.8% at constant exchange rates and scope of consolidation
• up 11.2% at constant exchange rates, including business development agreements

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2009.
Net sales for the first nine months of 2009 amounted to €895 million, an increase of 7.8% at constant exchange rates and scope of consolidation (like-for-like). Including the growth generated by recent business development agreements, the increase amounted to 11.2%.
The influenza A (H1N1) pandemic had a positive impact on sales, particularly of QuickVue® Influenza tests and NucliSENS® easyMAG® instruments. Excluding this impact, like-for-like growth was an estimated 6.7% over the first nine months and 9% in the third quarter alone.